Background. Platelet activating factor (PAF) is a phospholipid released upon stimulation by a variety of cells and has been implicated in several pathophysiological events such as asthma and inflammatory diseases. However, although the ability to aggregate platelets in vitro was the first biological activity ascribed to PAF, its role in contributing to the in vivo formation of arterial thrombi has not been thoroughly clarified.
Methods and Results. Intravascular platelet aggregation was initiated in two different animal models of arterial stenosis and endothelial injury. An external constrictor was positioned around rabbit carotid arteries and canine coronary arteries. After placement of the constrictor, a typical pattern of flow developed in the stenotic vessels. This pattern of flow, characterized by progressive reductions of carotid or coronary blood flow followed by spontaneous or induced restorations of flow (cyclic flow variations, CFVs), is related to recurrent platelet aggregation at the site of the stenosis followed by dislodgment of the thrombus. After observing CFVs for 30 minutes, BN52021 (up to 1.2 mg/kg), a potent and selective PAF antagonist, was given intravenously to rabbits (n=12) and dogs (n=10). BN52021 completely inhibited CFVs in 10 of 12 rabbits, whereas it was relatively ineffective in abolishing CFVs in dogs (only 2 of 10 animals inhibited). This different effect of BN52021 was not explained by too small a dose of the drug to achieve a complete blockade of PAF receptors in dogs, since ex vivo platelet aggregation was completely inhibited in both rabbits and dogs in response to exogenous PAF at concentrations up to 10`mol/L. In a second group of 10 dogs, the hypothesis that PAF may become an important mediator of CFVs in dogs only several hours after endothelial injury was tested. After 30 minutes of baseline CFVs, these animals received a bolus of BN52021 up to 1.2 mg/kg. After this treatment, CFVs were completely abolished in 2 of 10 animals. The remaining 8 dogs were followed for an additional 8-hour period, at the end of which a second bolus of BN52021 was given. At this time, BN52021 was effective, as CFVs were abolished in 6 of 8 animals. These effects of BN52021 at 8 hours were not the consequence of a cumulative dose of the compound, since ex vivo platelet aggregation in response to PAF returned to baseline values immediately before administering the second dose. To identify possible sources of PAF other than aggregating platelets at the site of arterial stenosis, dogs in a third group were killed after 30 minutes (n=7) and after 8 hours (n=8) of CFVs. Histological sections of the stenotic coronary artery showed a marked leukocyte infiltration in these arterial segments after 8 hours of CFVs, whereas sections from dogs killed after 30 minutes showed only moderate or no infiltration.
Conclusions. These data demonstrate that PAF plays an important role as a mediator of platelet aggregation in vivo in rabbits and dogs. In the canine model, PAF appears to become more important after leukocyte infiltration of the arterial wall, as it may contribute to initiating enough platelet activation to lead to cyclic flow variations at sites of arterial stenosis and endothelial injury. Data from the present study suggest that PAF antagonists may be used as antiplatelet agents. (Circulation. 1993 
Short-term Cyclic Flow Variations
To test the hypothesis that PAF is a mediator of CFVs, two different animal models were used in this arm of the study.
Rabbit studies. This model represents a modification14 of the well-described coronary canine model. 6 Briefly, 12 New Zealand White rabbits of either sex were anesthetized with a mixture of ketamine (35 mg/kg) and xylazine (5 mg/kg) given intramuscularly. Anesthesia was maintained during the course of the experiment by an intravenous infusion of ketamine sufficient to abolish the corneal reflex. Through a median incision of the neck, the left or right common carotid artery was exposed and carefully isolated from the surrounding tissue. Polyethylene catheters were placed into a jugular vein and a femoral artery for drug administration and continuous blood pressure monitoring, respectively. Thereafter, a segment of the exposed carotid artery was deendothelialized by gently squeezing the artery between a pair of rubber-covered forceps, and an external plastic constrictor was placed around it. Carotid blood flow velocity was measured continuously by a Doppler flow probe placed proximally to the constrictor (Fig 1) .
After instrumentation, all animals developed a typical pattern of blood flow (CFVs) characterized by gradual declines of flow to almost zero values, followed by either spontaneous or induced (by gently shaking the constrictor) restorations of flow (Fig 1) Long-term Cyclic Flow Variations
This set of experiments was performed to determine whether PAF may become an important mediator of CFVs several hours after endothelial injury. Ten additional dogs were included in this arm of the study. CFVs were initiated in canine coronary arteries as previously described. Thirty minutes later, an intravenous bolus of BN52021 (0.6 mg/kg) was given and eventually was repeated up to 1.2 mg/kg, as previously described. Thereafter, the animals in which CFVs were abolished were followed for an additional 30 minutes and the experiment was discontinued, whereas those in which CFVs were not abolished were followed for an additional 8 hours. After this time period, a second bolus of BN52021 was given intravenously, up to 1.2 mg/kg, and its effects on CFVs were recorded. During the whole experiment, CFV frequency and severity, heart rates, and arterial blood pressures were recorded continuously.
Ex vivo platelet aggregation. To ascertain whether the second administration of BN52021 was not additive with the first one, ie, that its effects had already disappeared at the time of the second administration (8 hours later), platelet aggregation in response to PAF was evaluated ex vivo under baseline conditions (no drug), after the first administration of BN52021 (30 minutes), and immediately before and after the last administration of the drug (8 hours). Platelets were collected, isolated, and aggregated ex vivo in response to PAF, ADP, serotonin, and U46619 as described above.
In Vitro PAF Production by Rabbit to a final concentration of 300,000 cells/pL. Thereafter, 0.5-mL aliquots were stirred in the aggregometer and challenged with thrombin (1 U/mL final concentration). After 10 minutes, the reaction was terminated by the addition of 1.5 mL of chloroform/methanol (1: 2 vol/vol).
Extraction and bioassay ofPAF. Lipids were extracted by the method of Bligh and Dyer20 and stored at -20°C. The organic phase was removed and evaporated to dryness under a continuous stream of nitrogen. Lipid extracts were redissolved in 50 ,uL of chloroform/methanol (1:1 vol/vol) and resolved by thin-layer chromatography on a silica gel G plate developed in chloroform/ methanol/acetic acid/water (50:25:8:3 vol/vol). The area corresponding to PAF was identified by comigration with an authentic standard run in parallel and was scraped off and dissolved in 0.5 mL methanol/water (3:1 vol/vol). The solvent was then evaporated to dryness, and the samples were reconstituted in 100 ,L of 0.9% NaCl supplemented with 0.25% BSA. PAF in the samples was detected by using washed rabbit platelets as a bioassay18 in the presence of aspirin (0.1 mmol/L) and phosphocreatine/creatine kinase (0.7 mmol/L to 13.9 U/mL) to inhibit arachidonic acid-dependent and ADP-dependent activation pathways, respectively. Under these conditions, washed rabbit platelets failed to aggregate in response to arachidonic acid (2 mmol/L) or ADP (100 gmol/L). 
Rabbit studies. Twelve rabbits were included in this arm of the study. After positioning the constrictor around the carotid artery, CFVs developed in all animals with a mean frequency of 18±3 cycles per hour and a severity, expressed as nadir carotid blood flow, of 5±1% of baseline values (Fig 2) (Fig 3) . In these same 8 animals, the severity of CFVs was also unaltered after administration of BN52021 (Fig 3) . Also in these animals, BN52021 did not cause significant changes in heart rate and blood pressure (Table) . These data indicate that PAF is not an important mediator of CFVs in this canine model at 30 minutes after endothelial injury and placement of the constrictor. Alternatively, dogs might be less responsive to BN52021 than rabbits.
Ex vivo platelet aggregation. Platelet aggregation was measured before and after administration of BN52021 in response to PAF, ADP, serotonin, and the thromboxane A2 analogue U46619 both in rabbits and dogs. In rabbits, according to the in vivo effects of BN52021 on CFVs, this compound inhibited PAF-induced aggregation, whereas it did not affect aggregation induced by the other agonists (Fig 4) . These data confirm that BN52021 is a selective PAF antagonist. In dogs, a dissociation between the effects on CFVs and inhibition of ex vivo PAF-induced platelet aggregation was observed. Although CFVs were abolished in only 2 of 10 dogs in vivo, a marked inhibition of PAF-induced aggregation was observed in vitro after administration of BN52021 (Fig 5) , thus excluding the possibility that the lack of effect on CFVs in these animals could be the consequence of a dose too low to achieve a sufficient degree of PAF receptor blockade. Also in dogs, BN52021 appeared to be selective for PAF receptors, as platelet aggregation in response to ADP, serotonin, and U46619 was not affected (Fig 5) 2 of 10 animals after 30 minutes of CFVS (Fig 6) . Fig 6) . These 6 dogs were followed for additional 30 minutes. None of them showed CFVs during this time period. Ex vivo platelet aggregation. Platelet aggregation in response to PAF was evaluated in these animals at baseline, after the first administration of BN52021, and at 8 hours before and after the second administration of the drug. As previously described, BN52021 completely inhibited PAF-induced aggregation with respect to baseline (Fig 7) . After 8 hours of CFVs, PAF-induced aggregation was no longer inhibited, thus demonstrating that at the time of administering the second dose of BN52021, the first dose was already metabolized. Again, the second dose of BN52021 resulted in a comparable inhibition of PAF-induced aggregation with respect to the first one (Fig 7) . In Vitro PAF Production by Rabbit and Canine Platelets The bioassay method used in the present study to quantify the amounts of PAF produced by activated platelets is widely used, and it has been shown to be highly sensitive even to trace quantities of PAF.18 Under our experimental conditions, washed rabbit platelets were sensitive to exogenously added PAF up to a concentration of 2.5 x 10-`M (data not shown).
Previous studies by other groups of investigators have shown that rabbit platelets stimulated with thrombin synthetize significant amounts of PAFl7,18 Consistent with those studies, we have also observed a significant production of PAF 
Animal Models of Intravascular Platelet Aggregation
In 1976, a canine model of intracoronary platelet aggregation was described.6 This model involves placement of an external constrictor around a segment of a coronary artery with focal endothelial injury. After placement of the constrictor, the stenosed vessels develop cyclic changes in coronary blood flow characterized by progressive reductions in flow followed by sudden returns of flow to basal levels (CFVs). Histological studies2' and studies with radiolabeled platelets7 have convincingly demonstrated that CFVs are due to the recurrent formation of a platelet-rich thrombus followed by its dislodgment at the site of the stenosis. It has been shown that thromboxane A2 and serotonin are important mediators in initiating and/or sustaining CFVs, as interventions that interfere with these mediators usually abolish CFVs in the majority of the animals.6-9'22 Recently, it has been shown that other mediators, including thrombin'0 and ADP," are also important in mediating CFVs in the canine model.
A similar model of intravascular platelet aggregation in rabbits has been described recently by our group.14 This model requires placement of a constrictor around deendothelialized segments of carotid arteries, and, similar to the data obtained in the canine coronary artery, we have also observed that thromboxane A2 and serotonin are important mediators in initiating and/or sustaining CFVs in stenotic rabbit carotid arteries with endothelial injury.14 One aspect of the present study deserves a particular comment. In 2 of 12 rabbits, CFVs were not abolished after administration of BN52021. This finding was not totally unexpected, as it has been reported previously in other studies using drugs that interfere with other chemical mediators. For example, thromboxane A2 synthesis inhibitors or receptor antagonists usually abolish CFVs in 70% to 80% of the animals, whereas they continue unchanged in the remaining animals. [6] [7] [8] 21, 22 This occurs also when serotonin receptor antagonists,9,22 thrombin inhibitors,'0 and interventions that remove the endogenous ADP released from activated platelets" are used. Also in the present study, the possibility of too low a dose of BN52021 to completely block PAF receptors can be excluded, since PAFinduced platelet aggregation was completely inhibited also in those rabbits in which CFVs were not abolished.
Thus, it is likely that, in those animals that do not respond to a single intervention, platelet aggregation can be sustained by the other mediators that are left free to exert their effects. This hypothesis is consistent with the observation that those animals that initially do not respond to a given intervention usually respond to addition of a second one in virtually all cases. 22 More intriguing was the finding that in dogs, in the short-term studies, a small number of animals did respond to BN52021, whereas the large majority did not. Also in this case, the dose of BN52021 administered was appropriate, since PAF-induced aggregation was similarly inhibited in the responders and in the nonresponders. One possible explanation is that, since some dogs at 30 minutes already showed a significant infiltration of leukocytes in the arterial wall at the site of the damage, these leukocytes could have released PAF that contributed to platelet aggregation (see below). However, it should be outlined that the histological studies were performed in a separate group of dogs and, therefore, this hypothesis remains largely speculative.
PAF and Cyclic Flow Variations PAF was originally recognized in experiments designed to characterize the cell-cell interaction after antigen stimulation of rabbit leukocytes containing IgEsensitized basophils.13 During this immunologically initiated reaction, a soluble mediator was released, and it was characterized by its ability to induce the aggregation of, and initiate the release reaction from, isolated rabbit platelets. Because its chemical nature was not known, the term "platelet activating factor" was coined to describe its functional activity.'3 Later, its physicochemical characteristics, including its phospholipid nature were discovered, and it is now accepted that PAF is 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine.23
Despite the fact that the first biological activity of PAF evidenced was its ability to activate platelets in vitro, the A novel observation of our study is that CFVs in the dog became responsive to PAF receptor antagonism after 8 hours. This suggests that the chemical mediators responsible for the occurrence of CFVs may change over time and that some of these substances (such as PAF) may become more important as the process of arterial damage/platelet activation/inflammation proceeds. However, if canine platelets are unable of synthesizing PAF at 30 minutes, logic holds that these cells probably do not acquire this ability after only few hours. As a consequence, other cellular sources of PAF should be involved in the generation of PAF during late CFVs.
Endothelial cells are possible candidates, as they are capable of synthetizing biologically relevant quantities of PAF upon adequate stimulation.30 However, the fact that the animal models used in the present study are associated with a deep vascular injury with a complete disruption of the endothelial lining would argue against this hypothesis.
Activated leukocytes are other possible candidates. Indeed, these cells are able to produce large amounts of PAF that can be released into the medium.31 Furthermore, while on one hand it has been reported that canine neutrophils possess acetyltransferase, the enzyme responsible for the synthesis of PAF,32 on the other, it is well known that platelets and leukocytes may interact with each other and influence one another's activity.33,34 For instance, degranulation of basophils sensitized by IgE antibodies triggers activation of platelets, which leads to immune complex deposition in acute serum sickness in rabbits, a disease that involves renal and peripheral arteries. 33 The interactions of leukocytes with platelets in various experimental preparations and in human pathological states are not well understood, but it has been shown that activated neutrophils release a variety of substances, among which thromboxane A2
and PAF are potent platelet agonists. Thus, it is conceivable that leukocytes might progressively accumulate over time at the site of the arterial damage and that, once activated, they release several chemical mediators, including PAF, the concentration of which may become locally quite high. This leukocyte-derived PAF may in turn contribute to the late sustaining of CFVs. This hypothesis is supported by the observation in our study that the marked leukocyte infiltration at the damaged coronary arterial site observed at 8 hours is accompanied by the responsiveness of CFVs to PAF receptor antagonism. Indeed, a maximal degree of leukocyte infiltration was observed in histological sections obtained from animals killed after 8 hours of CFVs, whereas those obtained from dogs killed after 30 minutes of CFVs showed only little or no infiltration.
Conclusions
The present study demonstrates that PAF plays an important albeit complex role in mediating the in vivo platelet activation in canine models with endothelial injury and coronary artery stenosis sufficient to lead to CFVs and suggests for the first time that leukocytes may contribute to the formation of arterial thrombi by releasing one or more factors, such as PAF at the site of arterial stenosis and endothelial injury. Since human platelets produce PAF,17,18 it can be speculated that PAF is a short-term mediator of in vivo platelet aggre-gation in humans similar to that observed in rabbits. In addition, because PAF is formed by and acts on both platelets and leukocytes, this substance may represent one of the critical links in cell to cell interactions, thus providing the cellular basis for potently amplifying mechanisms of injury. The present study also outlines the usefulness of PAF receptor antagonists as possible antithrombotic interventions. Whether these drugs will be effective in reducing the inflammatory component associated with the formation of arterial thrombi is not known, but this should be evaluated in future studies.
